research 180 Impact of underlying medical conditions and medications on edema development in alopecia patients receiving low-dose oral minoxidil (LDOM)
Low-dose oral minoxidil is safe for alopecia patients, even those prone to edema.
Search
for
Sort by
Research
870-900 / 1000+ results
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research Role of ciclosporin in steroid-responsive sudden sensorineural hearing loss
Ciclosporin might be a good alternative treatment for certain hearing loss that responds to steroids.
research A preview of selected articles
The document concludes that DNA methylation and the mTOR pathway are important for stem cell function and could impact disease treatment.
research Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
Deucravacitinib helped a man regrow hair and improve psoriasis.
research Intermittent nitrate transdermal therapy
Using minoxidil for hair growth may cause skin lesions in some people, and taking breaks from nitrate patches for angina might worsen symptoms.
research ADVANCES IN PSORIASIS THERAPY
New psoriasis treatments are effective but come with side effects and risks.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Sustained release of inhibitor from bionic scaffolds for wound healing and functional regeneration
Researchers developed a scaffold that releases a healing drug over time, improving wound healing and skin regeneration.
research Oral cyclosporin does not arrest progression of androgenetic alopecia.
Oral cyclosporin doesn't stop hair loss.
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Safety and efficacy of actinic keratoses reduction with a 3 day application of ingenol disoxate field treatment to the face, chest and balding scalp
The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss
research Sorafenib-induced eruption resembling pityriasis rubra pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
research A new model for cyclophosphamide-induced alopecia and its manipulation by cyclosporine a and topical dexamethasone
research Etoricoxib
A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Impact of Ester Promoieties on Transdermal Delivery of Ketorolac
Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Rethinking Oral Minoxidil: Distinguishing the Hair-Growth Window from the Cardiovascular Threshold
research Minoxidil Skin Delivery from Nanoemulsion Formulations Containing Eucalyptol or Oleic Acid: Enhanced Diffusivity and Follicular Targeting
Eucalyptol and oleic acid in nanoemulsions improve minoxidil delivery to hair follicles, potentially enhancing hair loss treatment.
research The successful treatment of nephrogenic fibrosing dermopathy (NFD) with mycophenolate mofetil (MMF)
Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
research Abstract 13315: Recurrent Cardiac Tamponade Due to Minoxidil Associated Drug Induced Lupus Erythematosus
Minoxidil can cause a rare but serious condition that leads to fluid buildup around the heart and drug-induced lupus.
research The Effectiveness and Safety of Three Treatment Regimens of Topical Minoxidil 5.0%, Betamethasone 0.064% w/w, and Castor and Jojoba Oils for Alopecia Areata: A Multicenter Cohort Study
Minoxidil with betamethasone is the most effective for hair regrowth in alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.